Full Press Release Details
InMed Pharmaceuticals Files Additional Patent
INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease
Vancouver, British Columbia-October 28,
2024 (InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on
developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that it has
filed an additional international patent application, under the Patent Cooperation Treaty (PCT), focused on the pharmaceutical composition
and method of use for the proprietary small molecule drug candidate INM-901 for treating neurodegenerative diseases, including Alzheimer's
This PCT patent application encompasses several
key components, including:
Additionally, the patent application specifies
methods for neuroprotection, stimulating neurogenesis, enhancing basal and locomotor activity, improving anxiety-related behaviors, cognitive
function, memory, and sound awareness, as well as downregulating inflammation markers and upregulating neuronal function markers.
"The INM-901 drug development program represents
a novel approach to treating Alzheimer's disease and the conversion of this PCT application is an important step to protect our
research and development in the area of neurodegeneration," stated Dr. Eric Hsu, Senior Vice President of Preclinical Research &
Development at InMed. "We have recently made significant progress with the INM-901 and are committed to advancing this program towards
human clinical trials. We look forward to presenting long-term in vivo data in the coming weeks."
This development further enhances InMed patent
portfolio which currently includes fourteen patent families, eight of which focus on drug composition/formulations/methods of use and
six address manufacturing technologies.
INM-901: Targeting several biological pathways
associated with Alzheimer's disease
INM-901 is a proprietary small molecule drug candidate
with multiple mechanisms of action as a potential treatment for Alzheimer's disease. Key characteristics of INM-901 include:
Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the
CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological
indications. For more information, visit www.inmedpharma.com.
Vice President, Investor Relations
and Corporate Communications
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning
of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects",
"anticipates", "believes", "intends", "potential", "possible", "would"
and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks,
uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's
current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release
includes, but is not limited to, statements about; filing an additional patent application for INM-901; What the new patent encompasses;
the efficacy of INM-901, INM-901's ability to treat AD, marketability and uses for INM-901, the results of further studies into
INM-901 and acceleration of the development of InMed's AD program as well as potential GLP studies or IND submissions.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks
and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings
with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified
in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,
events or developments, except as required by law.